Study on Momelotinib and Luspatercept for Patients with Transfusion Dependent Myelofibrosis

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of primary myelofibrosis or myelofibrosis that developed after polycythemia vera or essential thrombocythemia.
• Either have never used JAK inhibitors or have used them for at least 90 days, or 28 days if they caused a need for frequent blood transfusions or severe side effects.
• Be at high, intermediate-2, or intermediate-1 risk according to specific scoring systems.
• Require regular blood transfusions or have low hemoglobin levels before starting the study treatment.

Exclusion Criteria

• Have a history of certain intestinal or stomach diseases that affect medication absorption.
• Have had another invasive cancer within the last 5 years.
• Have anemia due to specific deficiencies or conditions like iron deficiency or thalassemia.
• Have uncontrolled infections or liver disease.
• Have uncontrolled high blood pressure.
• Have had certain heart conditions or strokes in the last 6 months.
• Have a prolonged QT interval on an ECG.
• Have a history of porphyria or significant nerve damage.
• Have used certain treatments or medications recently, including other myelofibrosis therapies or investigational drugs.
• Have had a splenectomy or previous treatment with momelotinib or luspatercept.
• Be unable to follow study rules or have unresolved side effects from previous treatments.
• Have certain viral infections like HIV or active hepatitis.
• Be pregnant or breastfeeding.